Last reviewed · How we verify
NCT05214430
Exclusive Enteral Nutrition for Remissionof Crohn's Diseases After Surgery
NA trial testing 3 months exclusive enteral nutrition after surgery in Crohn Disease in Remission in 84 participants. Completed in 31 July 2023.
31 July 2020
Quick facts
| Lead sponsor | Jinling Hospital, China |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 84 |
| Start date | 1 January 2020 |
| Primary completion | 31 July 2020 |
| Estimated completion | 31 July 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- 3 months exclusive enteral nutrition after surgery
Conditions studied
- Crohn Disease in Remission — all drugs for Crohn Disease in Remission →
Sponsor
Jinling Hospital, China
Who can join
Adults 18 to 60, any sex, with Crohn Disease in Remission. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
For patients with Crohn's diseases undergoing surgery，whether postoperative exclusive enteral nutrition(EEN) could delay the endoscopic relapse needs exploration.The trial will investigate the efficacy of postoperative EEN for maintaining disease remission.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Azathioprine Plus Exclusive Enteral Nutrition Versus Azathioprine Monotherapy for the Prevention of Postoperative Recurrence in Patients with Crohn's Disease: An Open-Label, Single-Centre, Randomized Controlled Trial.
Duan M, Lu M, Diao Y, Cao L, et al · · 2024 · cited 9× · PMID 38253914 · DOI 10.1093/ecco-jcc/jjae015
Verify or expand the search:
- PubMed search for NCT05214430
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Jinling Hospital, China trials
Trials by the same sponsor.
- NCT07297238 — Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration. · NA · recruiting
- NCT07237542 — Effect of Remote Ischemic Preconditioning on Early Neurological Deterioration in Acute Perforating Artery Infarction · NA · recruiting
- NCT07230314 — Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inh · Phase 2 · not yet recruiting
- NCT06177522 — Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07124624 — Stepped-Wedge Cluster Randomized Trial of AI-Assisted CTA Detection for Intracranial Aneurysms in Regional Hospitals · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05214430 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jinling Hospital, China
- Last refreshed: 17 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05214430.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing